19:51:37 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2024-11-21 15-10 2024-Q3
2024-08-22 Kvartalsrapport 2024-Q2
2024-05-24 X-dag ordinarie utdelning 2CUREX 0.00 SEK
2024-05-23 Årsstämma 2024
2024-02-29 Extra Bolagsstämma 2024
2024-02-22 Bokslutskommuniké 2023
2023-11-23 Kvartalsrapport 2023-Q3
2023-11-14 Extra Bolagsstämma 2023
2023-08-24 Kvartalsrapport 2023-Q2
2023-05-29 Kvartalsrapport 2023-Q1
2023-05-26 X-dag ordinarie utdelning 2CUREX 0.00 SEK
2023-05-25 Årsstämma 2023
2023-02-23 Bokslutskommuniké 2022
2023-02-10 Extra Bolagsstämma 2022
2022-11-24 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-25 X-dag ordinarie utdelning 2CUREX 0.00 SEK
2022-05-24 Kvartalsrapport 2022-Q1
2022-05-24 Årsstämma 2022
2022-02-24 Bokslutskommuniké 2021
2021-11-25 Kvartalsrapport 2021-Q3
2021-08-26 Kvartalsrapport 2021-Q2
2021-05-28 X-dag ordinarie utdelning 2CUREX 0.00 SEK
2021-05-27 Årsstämma 2021
2021-05-27 Kvartalsrapport 2021-Q1
2021-02-25 Bokslutskommuniké 2020
2020-11-26 Kvartalsrapport 2020-Q3
2020-08-27 Kvartalsrapport 2020-Q2
2020-07-02 Extra Bolagsstämma 2020
2020-05-29 X-dag ordinarie utdelning 2CUREX 0.00 SEK
2020-05-28 Kvartalsrapport 2020-Q1
2020-05-28 Årsstämma 2020
2020-02-28 Bokslutskommuniké 2019
2019-11-22 Kvartalsrapport 2019-Q3
2019-08-23 Kvartalsrapport 2019-Q2
2019-05-29 X-dag ordinarie utdelning 2CUREX 0.00 SEK
2019-05-28 Årsstämma 2019
2019-05-17 Kvartalsrapport 2019-Q1
2019-04-02 Extra Bolagsstämma 2019
2019-03-01 Bokslutskommuniké 2018
2018-11-23 Kvartalsrapport 2018-Q3
2018-08-24 Kvartalsrapport 2018-Q2
2018-05-29 X-dag ordinarie utdelning 2CUREX 0.00 SEK
2018-05-28 Årsstämma 2018
2018-05-18 Kvartalsrapport 2018-Q1
2018-02-15 Bokslutskommuniké 2017

Beskrivning

LandDanmark
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
2cureX är verksamt inom cancerbehandling. Idag tillhandahåller bolaget olika verktyg som används av läkare vid behandlingar för att mäta effekt och resistens hos cancerläkemedel på patientens egna cancerceller. Målet är att förkorta behandlingsperioden samt hitta rätt individuell behandling. Störst verksamhet innehas på den europeiska marknaden. Huvudkontoret ligger i Köpenhamn.
2023-12-29 14:30:00

2cureX, a company pioneering the use of 3D tumoroids for drug sensitivity prediction in patients with cancer, announces changes to management and a narrowing of the company’s focus to ZENITH and the ambition of making IndiTreat® testing available at hospitals worldwide.

The Board of Directors of 2cureX announces changes to the management:

  • Effective 29 December 2023, CEO Fernando Andreu is leaving the company.
  • Effective 1 January 2024, CSO Ole Thastrup will be leaving his CSO position to become Vice-Chairman of the Board of Directors.

The change of Ole Thastrup’s affiliation will ensure that 2cureX is following Good Corporate Governance.

The current CFO Kenneth G. Johansen is appointed acting CEO as of 29 December 2023.

The Board of Directors will in the beginning of 2024 initiate a recruitment process of a new Executive Management Team to execute 2cureX’s ambitious ZENITH plan on making IndiTreat® testing available at hospitals worldwide.

The full focus on ZENITH has necessitated downsizing and focus of the organization, a change that has extended the runway to the end of 2024.

Chairman of the Board of Directors, Tonni Bülow-Nielsen says “On 14 November 2023 I was appointed Chairman Board and for the last six weeks the Board has been evaluating the company’s strategic focus. During this period, we concluded that a corporate redirection was needed to support a successful rollout of the Zenith plan and also to ensure alignment to Good Corporate Governance practices.

2cureX has a strong technical and clinical foundation to become a global leader in providing Drug Sensitivity guidance for treatment of cancer patients, and that opens for an attractive offering to investors and partners and by downsizing the organization we have gained a runway until the end of 2024 and the time to make the right decisions”.

2cureX will release its Q4 2023 report on 22. February 2024 and an update strategy plan will be presented in Q1 2024.